Preclinical pharmacokinetics, distribution, metabolism and excretion of disitamab vedotin.

Authors

Ling Wang, Limeng Zhu, Fengzhu Wang, Lihou Dong, Zhihao Liu, Fang Chen, Jing Jiang

Published in

ADMET & DMPK. Volume 13. Issue 2. Pages 2582. Epub Mar 14, 2025.

Abstract

Disitamab vedotin is an antibody-drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody (mAb) targeting HER2 conjugated to monomethyl auristatin E(MMAE) via a cleavable dipeptide linker.
The pharmacokinetics, distribution, catabolism/metabolism and elimination properties of disitamab vedotin and its payload MMAE were characterized in rats and tumour-bearing mice.
The configured mAb and total antibody showed linear dynamic characteristics. Moreover, the molecular structure of disitamab vedotin effectively reduces the exposure of MMAE, which has a fast clearance. Two radiolabeled probes were developed to track the fate of different components of the disitamab vedotin, including ¹²⁵I labelled antibody and ³H labelled MMAE payload of the ADC. Following a single intravenous administration of the radiolabeled probes to the tumour-bearing mice and rats, blood, various tissues, and excreta samples were collected and analyzed for radioactivity and to characterize the metabolites/catabolites. Disitamab vedotin and free MMAE (FM) were majorly distributed in tissues and organs with rich blood flow. Moreover, both disitamab vedotin and MMAE have higher and longer exposure in tumour tissue. Disitamab vedotin was mainly eliminated through renal excretion, while the FM was mainly eliminated through the biliary faecal route (>70 %) and a small fraction (<10 %) was eliminated through renal excretion in the form of catabolites/metabolites, among which, MMAE was identified as the major species, along with 10 other minor species.
These studies provided significant insight into disitamab vedotin pharmacokinetics, distribution, metabolism and elimination properties, which supports the clinical development of disitamab vedotin.

PMID:
40314006
Bibliographic data and abstract were imported from PubMed on 02 May 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.